Pitolisant

Introduction Overview

Generic Name

pitolisant

Brand Name

Wakix

Dosage Form

tablet (4.45 mg, 17.8 mg)

Drug Class

Miscellaneous central nervous system agents

Pharmacokinetics

Absorption:
Pitolisant is well absorbed orally after administration of Wakix tablets. Peak plasma concentrations are typically reached within approximately 3 hours post-dose, indicating moderately rapid absorption. Food does not significantly affect the extent of absorption, allowing flexibility regarding administration with or without meals. The drug exhibits linear pharmacokinetics over the therapeutic dose range of 4.45 mg to 35.6 mg administered once daily. The bioavailability is sufficient to achieve therapeutic plasma concentrations correlating with clinical efficacy in narcolepsy.

Distribution:
Pitolisant exhibits moderate plasma protein binding (~90%) primarily to albumin, contributing to its distribution characteristics. The volume of distribution is approximately 87 L, indicating distribution beyond the vascular compartment into tissues, including the central nervous system, consistent with its pharmacodynamic effects. The ability of pitolisant to cross the blood-brain barrier is central to its mechanism of action in promoting wakefulness by modulating histamine levels in the brain. The drug's distribution may be influenced by patient-specific factors such as body mass and protein binding capacity.

Metabolism:
Pitolisant undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, notably CYP2D6 and CYP3A4 isoenzymes. It is metabolized to several inactive metabolites, with demethylation being a key pathway. Individuals who are poor CYP2D6 metabolizers can experience altered metabolism leading to increased plasma levels of pitolisant. Co-administration with strong CYP2D6 inhibitors or CYP3A4 inducers can affect pitolisant’s plasma concentration, necessitating dose adjustments or caution. The hepatic metabolism underlies the necessity for dose modification or avoidance in patients with severe hepatic impairment.

Elimination:
The elimination half-life of pitolisant ranges around 10 to 14 hours, supporting once-daily dosing. The drug and its metabolites are primarily excreted via urine, with renal clearance accounting for a substantial elimination pathway. Only a small fraction of unchanged pitolisant is excreted renally. In patients with renal impairment, elimination can be moderately affected, necessitating careful monitoring and possible dosing modifications. The pharmacokinetics in severe renal impairment is not well-characterized, so caution is advised. The elimination profile complements steady plasma levels conducive to therapeutic control of narcolepsy symptoms.

Dosage Forms

Available Dosage Forms:
Wakix is available as oral tablets formulated to contain 4.45 mg and 17.8 mg of the active ingredient pitolisant hydrochloride. Each tablet is designed for once-daily administration with consistent bioavailability.

Dosages for Adults and Adolescents:
For adult patients with narcolepsy exhibiting excessive daytime sleepiness (EDS) and/or cataplexy, the recommended titration includes starting with 8.9 mg once daily (two 4.45 mg tablets) during week 1, increasing to 17.8 mg (one 17.8 mg tablet) once daily in week 2, and then to a maximum of 35.6 mg (two 17.8 mg tablets) once daily in week 3, dependent on tolerability and therapeutic response. The tablets are taken orally once daily upon waking. Dose adjustments should be gradual to monitor and optimize efficacy and safety.

Specific Patient Populations:
In pediatric patients 6 years of age and older with narcolepsy and EDS, dosing starts with 4.45 mg once daily in week 1, increased to 8.9 mg once daily in week 2, then to 17.8 mg daily in week 3, which is the maximum recommended dose for patients under 40 kg. For those weighing 40 kg or more, dosing can be escalated to 35.6 mg once daily at week 4. Dose adjustments may be required for hepatic or renal impairment and poor CYP2D6 metabolizers. In patients with severe liver disease, usage is contraindicated. Caution and clinical monitoring are necessary during dosing titration, particularly in special populations.

Mechanism Of Action

Pitolisant, the active ingredient in Wakix, functions primarily as an antagonist/inverse agonist at histamine H3 receptors, a subtype of presynaptic autoreceptors located predominantly in the central nervous system. By binding to H3 receptors, pitolisant inhibits their activity, leading to increased synthesis and release of histamine, a key neurotransmitter involved in regulating wakefulness and arousal.

Histamine neurons in the tuberomammillary nucleus of the hypothalamus play a critical role in maintaining wakefulness and cognitive function. H3 receptor antagonism by pitolisant enhances histamine release, which subsequently activates postsynaptic histamine H1 receptors, promoting an arousal effect and counteracting excessive daytime sleepiness. This mechanism differs markedly from traditional stimulant medications that directly increase dopamine or norepinephrine levels, offering a non-stimulant alternative with a distinct safety profile.

Moreover, pitolisant influences other neurotransmitter systems indirectly, including modulation of acetylcholine, norepinephrine, and dopamine release, thereby contributing to improved alertness and stabilization of muscle tone. This multifaceted modulation underpins its efficacy in treating both excessive daytime sleepiness and cataplexy, the latter being believed to involve stabilization of muscle tone during wakefulness.

Clinical studies have demonstrated that pitolisant produces beneficial neurochemical changes translating into symptomatic improvement in narcolepsy patients. It is notable as the first H3 receptor antagonist approved for this indication, representing an innovative pharmacologic approach distinct from traditional stimulants and sodium oxybate therapies. The drug’s therapeutic effects emerge from restoration of normal histaminergic signaling pathways, a novel target in sleep-wake regulation.

Pharmacological Actions

Selective antagonism and inverse agonism at central nervous system histamine H3 receptors.
Enhancement of histamine synthesis and release leading to increased histaminergic neurotransmission.
Indirect modulation of neurotransmitters including acetylcholine, dopamine, and norepinephrine.
Promotion of wakefulness and alertness through central nervous system stimulation.
Reduction of excessive daytime sleepiness and cataplexy in narcolepsy patients.
Non-stimulant mechanism distinct from amphetamines and modafinil.
Improvement in muscle tone regulation reducing sudden loss of muscle strength events.
Minimal abuse potential owing to lack of stimulant properties.
Facilitation of neurotransmitter homeostasis in sleep-wake regulatory pathways.
Prolongation of wake-promoting neurotransmission without significant cardiovascular stimulation.
Potential modulation of cognitive and executive function due to enhanced histaminergic activity.
Demonstrated central nervous system penetrance suitable for targeting sleep disorders.
Therapeutic effect through novel histamine H3 receptor blockade representing a new drug class.

Therapeutic Or Clinical Uses

Treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
Management of cataplexy symptoms associated with narcolepsy in adults.
Treatment of excessive daytime sleepiness in pediatric patients 6 years of age and older with narcolepsy.
Non-stimulant treatment option for narcolepsy offering reduced risk of abuse and dependence.
Adjunct or alternative therapy for patients unable to tolerate traditional stimulant medications.
Improvement of daytime wakefulness and reduction in sleep attacks in narcoleptic patients.
Reduction in frequency and severity of cataplexy episodes to support daily functioning.
Therapy suited for long-term management of narcolepsy with a favorable safety profile.
Treatment option for patients with contraindications to stimulant therapies.
Use in patients requiring improved quality of life through reduction of narcolepsy symptoms.
Clinical indication supported by FDA approval based on robust efficacy and safety data.
Applicable in pediatric population where limited treatment options exist for EDS.
Use in narcolepsy patients with comorbid conditions where stimulant use is inadvisable.
Therapeutic benefit in stabilizing muscle tone and reducing sudden muscle weakness.
Potential to improve adherence due to once-daily dosing and tolerability.

Side Or Adverse Effects

Common side effect of nausea may occur, especially during dose titration phases.
Anxiety and increased nervousness reported in some patients.
Insomnia or other sleep disturbances may develop secondary to wakefulness promotion.
Potential for allergic reactions including rash, hives, or facial edema.
Rare but serious hypersensitivity reactions such as anaphylaxis have been reported.
Palpitations or rapid/irregular heartbeat including fluttering sensation.
Shortness of breath or respiratory discomfort reported in isolated cases.
Dizziness or episodes resembling presyncope, requiring clinical evaluation.
Headache and gastrointestinal disturbances occasionally reported.
Fatigue or malaise possibly due to circadian rhythm adjustments during therapy.
Rare psychiatric symptoms including agitation or mood changes.
Drug-related QT interval prolongation concerns in predisposed individuals.
Potential interactions increasing side effect risk when combined with QT-prolonging agents.
Hypersensitivity reactions more common in patients with previous allergy history.
Discontinuation symptoms not typically reported but gradual dose tapering advised.

Precautions

Use cautiously in patients with pre-existing cardiac arrhythmias or long QT syndrome.
Avoid use in patients with severe hepatic impairment due to altered metabolism.
Caution advised in patients with moderate to severe renal impairment.
Monitor for psychiatric or neurologic adverse effects during initiation and titration.
Consider alternative contraception methods as pitolisant can reduce hormonal birth control efficacy.
Pregnant women should consult healthcare providers; data on fetal safety limited.
Breastfeeding mothers should discuss risks and benefits with healthcare providers before use.
Dose adjustments may be necessary for poor CYP2D6 metabolizers due to altered clearance.
Slow dose titration recommended to minimize adverse events and improve tolerability.
Patients advised to avoid driving or operating machinery until response to therapy is known.
Monitor for signs of hypersensitivity and instruct patients to report any allergic symptoms immediately.
Beware of drug-drug interactions, especially with CYP2D6 inhibitors and CYP3A4 inducers.
Use with caution in patients with a history of seizure disorders.
Regular follow-up recommended to assess therapeutic response and adverse effects.
Inform patients about the importance of adherence and not to double dose if a dose is missed.

Warnings

Contraindicated in patients with severe liver disease due to impaired drug metabolism.
Known hypersensitivity to pitolisant or any inactive formulation components contraindicates use.
Risk of serious allergic reactions including anaphylaxis has been documented.
Prolonged QT interval and cardiac arrhythmias may occur; use with caution in susceptible patients.
Avoid use concomitantly with drugs known to prolong QT interval or cause arrhythmias.
May reduce effectiveness of hormonal contraceptives; non-hormonal methods required during and 21 days after treatment.
Not recommended in patients with known long QT syndrome or family history of this condition.
Potential for drug interactions warrant careful review of concurrent medications before initiation.
Not classified as a controlled substance but requires prescription and medical supervision.
Gradual dose escalation is necessary to reduce risk of side effects and improve safety.
Patients should be informed of signs of cardiac symptoms and instructed to seek immediate medical care if they occur.
Use during pregnancy only if clearly needed; potential risks to fetus are not fully established.
Breastfeeding safety is not well-established; medical advice recommended before use.
Overdose can cause serious adverse effects; emergency care should be sought immediately.
Avoid abrupt discontinuation to prevent rebound symptoms or sudden loss of control of narcolepsy.

Contraindication

Severe hepatic impairment or liver disease.
Known hypersensitivity or allergy to pitolisant or any inactive ingredients in Wakix tablets.
History of anaphylactic reaction attributed to pitolisant therapy.
Patients with congenital long QT syndrome or family history of sudden cardiac death.
Concurrent use with medications that strongly prolong QT interval without appropriate monitoring.
Use in populations where safety has not been established, such as severe renal failure without monitoring.
Known intolerance to any components of the formulation including excipients.
Patients with hypersensitivity to similar H3 receptor antagonists, if known.
Use not recommended in neonates and infants below 6 years due to lack of safety data.
Concurrent use of centrally acting H1 receptor antagonists that negate pitolisant efficacy.
Concomitant use with strong CYP2D6 inhibitors without dose adjustment of pitolisant.
Contraindicated during breastfeeding unless benefits outweigh risks and under medical supervision.
Patients taking multiple QT-prolonging drugs without cardiac monitoring.
Severe uncontrolled cardiovascular disease posing increased risk with pitolisant use.
History of hypersensitivity reactions with prior pitolisant exposure.

Drug Interactions

Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase pitolisant plasma levels, necessitating dose adjustment.
Strong CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce pitolisant plasma concentrations and efficacy.
Sensitive CYP3A4 substrates such as hormonal contraceptives may have reduced effectiveness when co-administered.
Centrally acting H1 antihistamines (e.g., diphenhydramine, promethazine) may antagonize pitolisant’s wake-promoting effects.
Tri- or tetracyclic antidepressants like imipramine, clomipramine, and mirtazapine may reduce efficacy via H1 antagonism.
Co-administration with QT-prolonging agents increases risk of cardiac arrhythmias; monitor closely.
Medications for asthma, infections, hypertension, depression, cancer, malaria, or HIV may interact affecting pitolisant safety.
Concomitant use with other CNS stimulants requires careful monitoring for additive adverse effects.
Drugs affecting hepatic enzyme activity may alter pitolisant metabolism and require dosing review.
Hormonal contraceptives, including pills, implants, patches, rings, and injections, may have diminished efficacy.
Potential for pharmacodynamic interactions increasing risk of insomnia or anxiety when combined with other stimulants.
Avoid abrupt discontinuation when used with interacting agents to prevent rebound symptoms.
Over-the-counter medicines and herbal supplements should be disclosed due to possible interaction with cytochrome pathways.
Patients should inform healthcare providers of all medications to prevent adverse drug interactions.
Use of pitolisant with drugs causing sedation may attenuate therapeutic benefit and increase sedation risk.

Preparations Of The Drug

Wakix tablets containing 4.45 mg of pitolisant hydrochloride for initial dosing and pediatric use.
Wakix tablets containing 17.8 mg of pitolisant hydrochloride for maintenance and adult treatment doses.
Tablets formulated with inactive ingredients including colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Oral solid dosage form designed for once-daily dosing upon awakening.
Packaged for retail and prescription distribution by Harmony Biosciences, LLC.
Supplied with medication guides informing patients about dosing, side effects, and precautions.
Stored at controlled room temperature between 20°C to 25°C (68°F to 77°F), stability permitted between 15°C to 30°C (59°F to 86°F).
Manufactured to meet stringent quality control and regulatory standards to ensure consistency and safety.
Available in multiple tablet strengths to enable gradual titration and individualized dosing.
In standard blister packaging or bottles with child-resistant caps to ensure safety and dosage accuracy.
Marketed exclusively under the trademark Wakix registered by Bioprojet Pharma.
Preparation designed for oral administration with high bioavailability and central nervous system penetration.
Not a controlled substance, allowing for standard prescription dispensing procedures.
Intended for chronic use with regular dosing schedules optimized for therapeutic benefit and patient compliance.
Detailed prescribing information available through professional resources to guide safe and effective use.